1. Home
  2. CRNC vs CTNM Comparison

CRNC vs CTNM Comparison

Compare CRNC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cerence Inc.

CRNC

Cerence Inc.

HOLD

Current Price

$10.43

Market Cap

430.2M

Sector

Technology

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$11.53

Market Cap

489.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNC
CTNM
Founded
2020
2009
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
430.2M
489.4M
IPO Year
2019
2024

Fundamental Metrics

Financial Performance
Metric
CRNC
CTNM
Price
$10.43
$11.53
Analyst Decision
Hold
Buy
Analyst Count
4
4
Target Price
$10.25
$19.00
AVG Volume (30 Days)
1.3M
149.1K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
96.95
0.46
EPS
N/A
N/A
Revenue
$251,781,000.00
N/A
Revenue This Year
$27.18
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.85
$3.57
52 Week High
$13.74
$16.33

Technical Indicators

Market Signals
Indicator
CRNC
CTNM
Relative Strength Index (RSI) 48.05 33.95
Support Level $9.06 $10.17
Resistance Level $11.49 $13.26
Average True Range (ATR) 0.94 0.74
MACD -0.03 -0.22
Stochastic Oscillator 34.47 0.58

Price Performance

Historical Comparison
CRNC
CTNM

About CRNC Cerence Inc.

Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: